Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction

American Journal of Cardiology

Volumn 84, Issue 9, 1999, Pages 1074-1076

  Ochiai, Masahiko ^a   Eto, Koji ^a   Takeshita, Satoshi ^a   Yokoyama, Naoyuki ^a   Oshima, Akio ^a   Kondo, Kiyoyuki ^a   Sato, Tomohide ^a   Isshiki, Takaaki ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; HEPARIN; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DRUG EFFECT; FEMALE; FIBRINOLYTIC THERAPY; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; THROMBOCYTE; TREATMENT INDICATION; VASCULAR SMOOTH MUSCLE;

ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CORONARY ANGIOGRAPHY; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREMEDICATION; STENTS; TETRAZOLES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 0032752190     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00501-9     Document Type: Article

References (20)

1. Saito S., Hosokawa G., Kim K., Tanaka S., Miyake S. Primary stent implantation without coumadin in acute myocardial infarction. J Am Coll Cardiol. 28:1996;74-81.
2. Stone G.W., Brodie B.R., Griffin J.J., Morice M.C., Constantini C., Goar F.G., Overlie P.A., Popma J.J., McDonnell J., Jones D., O'Neill W.W., Grines C.L. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction in-hospital and 30-day results of the PAMI stent pilot trial . J Am Coll Cardiol. 31:1998;23-30.
3. Mahdi N.A., Lopez J., Leon M., Pathan A., Harrell L., Jang I.K., Palacios I.F. Comparison of primary coronary stenting to primary balloon angioplasty with stent bailout for the treatment of patients with acute myocardial infarction. Am J Cardiol. 81:1998;957-963.
4. Antoniucci D., Santoro G.M., Bolognese L., Valenti R., Trapani M., Fazzini P.F. A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction results from Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) Trial . J Am Coll Cardiol. 31:1998;1234-1239.
5. Kastrati A., Schühlen H., Hausleiter J., Walter H., Zitzmann-Roth E., Hadamitzky M., Elezi S., Ulm K., Dirschinger J., Neumann F.J., Schömig A. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy six-month angiographic follow-up of the intracoronary stenting and antithrombotic regimen (ISAR) trial . Circulation. 96:1997;462-467.
6. Nishi T., Tabusa F., Tanaka T., Shimizu T., Nakagawa K. Studies on 2-oxoquinolinone derivatives as blood platelet aggregation inhibitors IV. Synthesis and biological activity of metabolites of 6-[4-(1-cyclohexyl-1H-5-tetrazolyl) butoxyl]-2-oxo-1, 2, 3, 4-tetrahydroquinolinone (OPC-13013). Chem Pharm Bull (Tokyo). 33:1985;1140-1147.
7. Kimura Y., Tani T., Kanbe T., Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung Drug Res. 35:1985;1144-1149.
8. Ikeda Y., Kikuchi M., Murakami H. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo randomized, double-blind cross-over study . Arzneimittelforschung Drug Res. 37:1987;563-566.
9. Ochiai M., Isshiki T., Takeshita S., Eto K., Toyoizumi H., Sato T., Miyashita H. Use of cilostazol, a novel antiplatelet agent, in a Post-Palmaz-Schatz stenting regimen. Am J Cardiol. 79:1997;1471-1474.
10. Tsuchikane E., Katoh O., Sumitsuji S., Fukuhara A., Funamoto M., Otsuji S., Tateyama H., Awata N., Kobayashi T. Impact of cilostazol on intimal proliferation after directional coronary atherectomy. Am Heart J. 135:1998;495-502.
11. Sekiya M., Funada J., Watanabe K., Miyagawa M., Akutsu H. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol. 82:1998;144-147.
12. The Thrombolysis in Myocardial Infarction (TIMI) trial phase 1 findings . N Engl J Med. 312:1985;932-936.
13. Nunn C.M., O'Neill W.W., Rothbaum D., Stone G.W., O'Keefe J., Overlie P., Donohue B., Grines L., Browne K.F., Vliestra R.E., Catlin T., Grines C.L. Long-term outcome after primary angioplasty report from the primary angioplasty in myocardial infarction (PAMI-I) trial . J Am Coll Cardiol. 33:1999;640-646.
14. Schwartz R.S., Holmes D.R. Jr, Topol E.J. The restenosis paradigm revisited an alternative proposal for cellular mechanism . J Am Coll Cardiol. 20:1992;1284-1293.
15. Gordon P.C., Gibson C.M., Cohen D.J., Carrozza J.P., Kuntz R.E., Baim D.S. Mechanism of restenosis and redilation within coronary stents quantitative angiographic assessment . J Am Coll Cardiol. 21:1993;1166-1174.
16. Takahashi S., Oida K., Fujiwara R., Maeda H., Hayashi S., Takai H., Tamai T., Nakai T., Miyabo S. Effects of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 20:1992;900-906.
17. Speir E., Modali R., Huang E.S., Leon M.B., Shawal F., Finkel T., Epstein S.E. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 265:1994;391-394.
18. Kayanoki Y., Che W., Kawata S., Matsuzawa Y., Higashiyama S., Taniguchi N. The effect of cilostazol, a cyclic nucleotide phosphodiesterase III inhibitor, on heparin-binding EGF-like growth factor expression in macrophages and vascular smooth muscle cells. Biochem Biophys Res Commun. 238:1997;478-481.
19. Morishita R., Higashi J., Hayashi S.I., Aoki M., Nakamura S., Moriguchi A., Matsushita H., Matsumoto K., Nakamura T., Ogihara T. Role of hepatocyte growth factor in endothelial regulation prevention of high d-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor . Diabetologia. 40:1997;1053-1061.
20. Kubota Y., Kichikawa K., Uchida H., Maeda M., Nishimine K., Makutani S., Sakaguchi S., Yoshioka T., Ohishi H., Kimura Y., Yoshikawa T. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study. Invest Radiol. 30:1995;532-537.